Zoetis Inc. (NYSE:ZTS) Shares Sold by TFC Financial Management Inc.

TFC Financial Management Inc. cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 37.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,219 shares of the company’s stock after selling 741 shares during the period. TFC Financial Management Inc.’s holdings in Zoetis were worth $199,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis during the 3rd quarter valued at about $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis during the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the 3rd quarter valued at about $33,000. Dunhill Financial LLC grew its position in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC boosted its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ZTS shares. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler lowered their price objective on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday. Stifel Nicolaus lowered their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, UBS Group started coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $214.00.

Zoetis Stock Down 0.2 %

ZTS stock opened at $173.99 on Thursday. The firm has a market cap of $78.50 billion, a PE ratio of 32.70, a PEG ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The firm’s 50 day moving average price is $169.11 and its 200-day moving average price is $179.11. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.15%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.